G&L Bs-glargine Completes Ph3; Adocia’s BC Lispro Cleared for Pivotal Ph3 in China; Dario Signs National Digital Behavioral Health Contract
A series of cardiometabolic-related news items have been observed: Gan & Lee announced the conclusion of its two Ph3 bs-glargine studies; Adocia announced that its partner, Tonghua Dongbao, received clearance to initiate a Ph3 trial for uRAI BioChaperone Lispro in China; and Dario announced it was selected as the digital behavioral health provider for an undisclosed US national health plan. Below, FENIX provides highlights and insights for the respective news items.
About The Author
Matthew has been a thought leader in the high-growth therapeutic areas of diabetes and cardiovascular medicine since 2006, making regular attendance at large and small CV/met scientific meetings and an architect of novel methods for assessing market opportunities. He has over a decade of experience in leading CV/met consulting engagements, is a published author in PM360 and Diabetes Technology & Therapeutics, and has been quoted in The Pink Sheet on anti-thrombotics.
If you receive our email blasts, you already have an account. Log in now
You can read the article’s full content online after purchase.